Prognosis of Streptococcus pneumoniae endocarditis in France, a multicenter observational study (2000-2015).
Anti-Bacterial Agents
/ therapeutic use
Cardiac Surgical Procedures
/ methods
Endocarditis, Bacterial
/ epidemiology
Female
Follow-Up Studies
Forecasting
France
/ epidemiology
Humans
Incidence
Male
Middle Aged
Pneumococcal Infections
/ epidemiology
Pneumococcal Vaccines
/ therapeutic use
Prognosis
Retrospective Studies
Streptococcus pneumoniae
/ isolation & purification
Survival Rate
/ trends
Infective endocarditis
Pneumococcus vaccination
Prognosis
Streptococcus pneumoniae
Journal
International journal of cardiology
ISSN: 1874-1754
Titre abrégé: Int J Cardiol
Pays: Netherlands
ID NLM: 8200291
Informations de publication
Date de publication:
01 08 2019
01 08 2019
Historique:
received:
07
12
2018
revised:
18
03
2019
accepted:
16
04
2019
pubmed:
6
5
2019
medline:
24
3
2020
entrez:
7
5
2019
Statut:
ppublish
Résumé
Streptococcus pneumoniae is responsible for <2% of infective endocarditis (IE). The aim of this study was to assess the prognosis of pneumococcal IE. This multicentric observational retrospective study included adult patients presenting with definite S. pneumoniae IE according to modified Dukes criteria from four French university hospitals over a 15-year period, January 2000-December 2015. Survival rate at 90 days and 2 years after diagnosis, appropriateness of antibiotherapy, and pneumococcal vaccination status were determined. Risk factors for mortality were studied by univariate analysis. Of 3886 patients admitted with IE during the study period, 50 (1.3%) had pneumococcal IE, mostly males (n = 38, 76%), with a mean age of 60 ± 14 years. Predisposing conditions for IE or for invasive pneumococcal disease (IPD) involved 24% and 78% of the cases, respectively. Only 2 patients were vaccinated against pneumococcus before IE and 13 (26%) after IE. Antimicrobial strategy was in accordance with the 2015 ESC Guidelines in 28%. Cardiac surgery was performed in 56%, and was associated with better survival (p = 0.012). In the 40 patients followed until 2 years, the survival rate was 67%, deaths occurring mostly before 90 days. Age ≥ 65 was a risk factor for mortality (p = 0.011). Pneumococcal IE remains rare but with a poor prognosis. Resort to surgery is yet to be determined. Predisposing conditions for IPD are the main factors leading to pneumococcal IE. They could be prevented by vaccine coverage improvement.
Sections du résumé
BACKGROUND
Streptococcus pneumoniae is responsible for <2% of infective endocarditis (IE). The aim of this study was to assess the prognosis of pneumococcal IE.
METHODS
This multicentric observational retrospective study included adult patients presenting with definite S. pneumoniae IE according to modified Dukes criteria from four French university hospitals over a 15-year period, January 2000-December 2015. Survival rate at 90 days and 2 years after diagnosis, appropriateness of antibiotherapy, and pneumococcal vaccination status were determined. Risk factors for mortality were studied by univariate analysis.
RESULTS
Of 3886 patients admitted with IE during the study period, 50 (1.3%) had pneumococcal IE, mostly males (n = 38, 76%), with a mean age of 60 ± 14 years. Predisposing conditions for IE or for invasive pneumococcal disease (IPD) involved 24% and 78% of the cases, respectively. Only 2 patients were vaccinated against pneumococcus before IE and 13 (26%) after IE. Antimicrobial strategy was in accordance with the 2015 ESC Guidelines in 28%. Cardiac surgery was performed in 56%, and was associated with better survival (p = 0.012). In the 40 patients followed until 2 years, the survival rate was 67%, deaths occurring mostly before 90 days. Age ≥ 65 was a risk factor for mortality (p = 0.011).
CONCLUSION
Pneumococcal IE remains rare but with a poor prognosis. Resort to surgery is yet to be determined. Predisposing conditions for IPD are the main factors leading to pneumococcal IE. They could be prevented by vaccine coverage improvement.
Identifiants
pubmed: 31056415
pii: S0167-5273(18)36912-2
doi: 10.1016/j.ijcard.2019.04.048
pii:
doi:
Substances chimiques
Anti-Bacterial Agents
0
Pneumococcal Vaccines
0
Types de publication
Journal Article
Multicenter Study
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
102-106Informations de copyright
Copyright © 2019 Elsevier B.V. All rights reserved.